Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed (PDF) the setback as part of a wider ...

Roche explains exactly how he harnessed the science of heat training to deliver his unlikely time at the scorching 100-mile ...

Roche's activity in this area is represented by RG6279, an anti-PD-1 antibody fused to an engineered, variant form of IL-2, which is in phase 1 clinical testing.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic ...

Roche Holding saw its EPS decline at a compound rate of 6.7% per year, over the last three years. This reduction in EPS is ...

The best La Roche-Posay skincare products, including anti-aging options and picks for acne-prone, oily, dry, mature, ...

The family that started the Roche Bros. supermarket chain over 70 years ago is selling a controlling interest in the local ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...